Research
Hormonal
GLP-1 receptor agonists (e.g., Semaglutide, Liraglutide) and SGLT-2 inhibitors (e.g., Empagliflozin, Canagliflozin) significantly reduce cardiovascular risk and mortality in type 2 diabetic patients with high cardiovascular risk factors.
For T2D patients with high cardiovascular risk, GLP-1 receptor agonists (Semaglutide, Liraglutide) and SGLT-2 inhibitors (Empagliflozin, Canagliflozin) are superior to standard treatments for preventing heart attacks, strokes, and cardiovascular death. These drugs offer significant mortality benefits.
StrongSupportsVERY_HIGH confidence
SUSTAIN 6, LEADER和EMPA-REG 研究证实了, 索马鲁肽、利拉鲁肽、恩格列净和坎格列净对伴有心血管高危因素的T2DM患者具有心血管获益.
Why this rating
Based on multiple large-scale, multi-center, randomized, double-blind, placebo-controlled trials (SUSTAIN-6, LEADER, EMPA-REG).
Source
Advances in treatment of obesity-related type 2 diabetes
Dajin Zou · Scientia Sinica Vitae · 2018
DOI 10.1360/n052018-00046
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Very Low Calorie Diets (VLCD) and significant weight loss (>15 kg) can induce remission of type 2 diabetes in obese patients, primarily by reducing liver fat and restoring insulin sensitivity.Good
- Bariatric surgery (Roux-en-Y gastric bypass and sleeve gastrectomy) provides long-term weight loss and high diabetes remission rates (51% at 12 years) by altering gut microbiota diversity and increasing specific beneficial bacteria like Bacteroides uniformis.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →